|
US7666400B2
(en)
|
2005-04-06 |
2010-02-23 |
Ibc Pharmaceuticals, Inc. |
PEGylation by the dock and lock (DNL) technique
|
|
US7906118B2
(en)
|
2005-04-06 |
2011-03-15 |
Ibc Pharmaceuticals, Inc. |
Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
|
|
WO2004096113A2
(en)
|
2003-04-28 |
2004-11-11 |
Medical Instill Technologies, Inc. |
Container with valve assembly for filling and dispensing substances, and apparatus and method for filling
|
|
US8435539B2
(en)
|
2004-02-13 |
2013-05-07 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
|
US8003111B2
(en)
|
2005-04-06 |
2011-08-23 |
Ibc Pharmaceuticals, Inc. |
Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo
|
|
US9481878B2
(en)
|
2004-02-13 |
2016-11-01 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
|
US8034352B2
(en)
|
2005-04-06 |
2011-10-11 |
Ibc Pharmaceuticals, Inc. |
Tetrameric cytokines with improved biological activity
|
|
US8491914B2
(en)
|
2004-02-13 |
2013-07-23 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for delivery of interference RNA
|
|
US8551480B2
(en)
|
2004-02-13 |
2013-10-08 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
|
US8652484B2
(en)
|
2004-02-13 |
2014-02-18 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
|
US8562988B2
(en)
|
2005-10-19 |
2013-10-22 |
Ibc Pharmaceuticals, Inc. |
Strategies for improved cancer vaccines
|
|
US9931413B2
(en)
|
2005-04-06 |
2018-04-03 |
Ibc Pharmaceuticals, Inc. |
Tetrameric cytokines with improved biological activity
|
|
US8481041B2
(en)
|
2005-04-06 |
2013-07-09 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
|
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
|
US8158129B2
(en)
|
2005-04-06 |
2012-04-17 |
Ibc Pharmaceuticals, Inc. |
Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo
|
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
|
US9623115B2
(en)
|
2005-04-06 |
2017-04-18 |
Ibc Pharmaceuticals, Inc. |
Dock-and-Lock (DNL) Complexes for Disease Therapy
|
|
WO2007127286A2
(en)
|
2006-04-24 |
2007-11-08 |
Medical Instill Technologies, Inc. |
Needle penetrable and laser resealable lyophilization device and related method
|
|
AU2009233925B2
(en)
*
|
2006-12-05 |
2014-03-13 |
Ibc Pharmaceuticals, Inc. |
Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
|
|
MX2010011145A
(es)
*
|
2008-04-11 |
2011-04-11 |
Merrimack Pharmaceuticals Inc |
Enlazadores de la albumina de suero humana y conjugados de la misma.
|
|
CN102186499B
(zh)
|
2008-08-20 |
2015-05-20 |
Ibc医药公司 |
用于癌症治疗的对接和锁定(dnl)疫苗
|
|
WO2010059315A1
(en)
*
|
2008-11-18 |
2010-05-27 |
Merrimack Pharmaceuticals, Inc. |
Human serum albumin linkers and conjugates thereof
|
|
CA2771999A1
(en)
|
2009-08-24 |
2011-03-10 |
Amunix Operating Inc. |
Coagulation factor vii compositions and methods of making and using same
|
|
US20120308517A1
(en)
|
2010-02-09 |
2012-12-06 |
Digna Biotech, S.L. |
Compositions for the treatment of infectious and tumoural diseases
|
|
US9486507B2
(en)
|
2011-06-10 |
2016-11-08 |
Biogen Ma Inc. |
Pro-coagulant compounds and methods of use thereof
|
|
EP2583677A3
(en)
|
2011-10-21 |
2013-07-03 |
Abbvie Inc. |
Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
|
|
US8466159B2
(en)
|
2011-10-21 |
2013-06-18 |
Abbvie Inc. |
Methods for treating HCV
|
|
DE202012012955U1
(de)
|
2011-10-21 |
2014-07-14 |
Abbvie Inc. |
Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
|
|
US8492386B2
(en)
|
2011-10-21 |
2013-07-23 |
Abbvie Inc. |
Methods for treating HCV
|
|
US20140303074A1
(en)
*
|
2011-12-16 |
2014-10-09 |
The J. David Gladstone Institutes |
Compositions and Methods For Inhibiting Immunodeficiency Virus Transcription
|
|
CN104271150A
(zh)
|
2012-01-12 |
2015-01-07 |
比奥根艾迪克Ma公司 |
嵌合因子viii多肽及其用途
|
|
EP2822577B1
(en)
|
2012-02-15 |
2019-02-06 |
Bioverativ Therapeutics Inc. |
Recombinant factor viii proteins
|
|
JP6256882B2
(ja)
|
2012-02-15 |
2018-01-10 |
アムニクス オペレーティング インコーポレイテッド |
第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途
|
|
WO2013185113A1
(en)
|
2012-06-08 |
2013-12-12 |
Biogen Idec Ma Inc. |
Procoagulant compounds
|
|
CA2875247A1
(en)
|
2012-06-08 |
2013-12-12 |
Biogen Idec Ma Inc. |
Chimeric clotting factors
|
|
CN104661674A
(zh)
|
2012-07-11 |
2015-05-27 |
阿穆尼克斯运营公司 |
具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
|
|
KR101520383B1
(ko)
|
2012-08-02 |
2015-05-15 |
에이비온 주식회사 |
Ｈｐｖ 감염과 관련된 암의 치료용 조성물
|
|
KR101363575B1
(ko)
*
|
2012-08-07 |
2014-02-24 |
가천대학교 산학협력단 |
신부전증에 대한 신규 바이오마커 및 그의 용도
|
|
KR101363576B1
(ko)
*
|
2012-08-07 |
2014-02-24 |
가천대학교 산학협력단 |
알츠하이머 질환에 대한 신규 바이오마커 및 그의 용도
|
|
WO2014036520A1
(en)
|
2012-08-30 |
2014-03-06 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies comprising anti-erbb3 agents
|
|
HK1213767A1
(zh)
|
2012-10-18 |
2016-07-15 |
Bioverativ Therapeutics Inc. |
使用固定劑量凝血因子的方法
|
|
WO2014127215A1
(en)
|
2013-02-15 |
2014-08-21 |
Biogen Idec Ma Inc. |
Optimized factor viii gene
|
|
WO2014144549A1
(en)
|
2013-03-15 |
2014-09-18 |
Biogen Idec Ma Inc. |
Factor ix polypeptide formulations
|
|
CN113817069A
(zh)
|
2013-06-28 |
2021-12-21 |
比奥贝拉蒂治疗公司 |
具有xten的凝血酶可裂解连接子和其用途
|
|
TW202003554A
(zh)
|
2013-08-14 |
2020-01-16 |
美商百歐維拉提夫治療公司 |
因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
|
|
HUE057005T2
(hu)
|
2013-09-25 |
2022-04-28 |
Bioverativ Therapeutics Inc |
Oszlopon történõ vírusinaktiváló eljárások
|
|
EP3065769A4
(en)
|
2013-11-08 |
2017-05-31 |
Biogen MA Inc. |
Procoagulant fusion compound
|
|
AU2015204646B2
(en)
|
2014-01-10 |
2020-08-27 |
Bioverativ Therapeutics Inc. |
Factor VIII chimeric proteins and uses thereof
|
|
US11008561B2
(en)
|
2014-06-30 |
2021-05-18 |
Bioverativ Therapeutics Inc. |
Optimized factor IX gene
|
|
BR112017007765B1
(pt)
|
2014-10-14 |
2023-10-03 |
Halozyme, Inc |
Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
|
|
MA40835A
(fr)
|
2014-10-23 |
2017-08-29 |
Biogen Ma Inc |
Anticorps anti-gpiib/iiia et leurs utilisations
|
|
MA40861A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Anticorps anti-glycoprotéines iib/iiia
|
|
EA201890423A1
(ru)
|
2015-08-03 |
2018-07-31 |
Биовератив Терапьютикс Инк. |
Слитые белки фактора ix, способы их получения и применения
|
|
RU2614141C1
(ru)
*
|
2015-12-28 |
2017-03-23 |
федеральное государственное бюджетное образовательное учреждение высшего образования "Тюменский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Тюменский ГМУ Минздрава России) |
Способ прогнозирования парафарингиального абсцесса при остром паратонзиллите
|
|
CA3012695A1
(en)
|
2016-02-01 |
2017-08-10 |
Bioverativ Therapeutics Inc. |
Optimized factor viii genes
|
|
EA201892448A1
(ru)
|
2016-04-28 |
2019-06-28 |
Эмори Юниверсити |
Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
|
|
MX2019006444A
(es)
|
2016-12-02 |
2019-10-30 |
Bioverativ Therapeutics Inc |
Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
|
|
JP2019536794A
(ja)
|
2016-12-02 |
2019-12-19 |
バイオベラティブ セラピューティクス インコーポレイテッド |
凝固因子に対する免疫寛容を誘導する方法
|
|
US20200031895A1
(en)
|
2016-12-16 |
2020-01-30 |
Biogen Ma Inc. |
Stabilized proteolytically activated growth differentiation factor 11
|
|
EA201991768A1
(ru)
|
2017-01-31 |
2020-01-22 |
Байоверетив Терапьютикс Инк. |
Слитые белки на основе фактора ix и способы их получения и пути применения
|
|
US10767164B2
(en)
|
2017-03-30 |
2020-09-08 |
The Research Foundation For The State University Of New York |
Microenvironments for self-assembly of islet organoids from stem cells differentiation
|
|
NZ762100A
(en)
|
2017-08-09 |
2025-12-19 |
Bioverativ Therapeutics Inc |
Nucleic acid molecules and uses thereof
|
|
AU2019215063B2
(en)
|
2018-02-01 |
2025-10-16 |
Bioverativ Therapeutics, Inc. |
Use of lentiviral vectors expressing Factor VIII
|
|
WO2019222296A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable interleukin 12 polypeptides and methods of use thereof
|
|
AU2019271148B9
(en)
|
2018-05-14 |
2025-05-29 |
Werewolf Therapeutics, Inc. |
Activatable interleukin-2 polypeptides and methods of use thereof
|
|
PL3793588T3
(pl)
|
2018-05-18 |
2025-09-01 |
Bioverativ Therapeutics Inc. |
Sposoby leczenia hemofilii a
|
|
KR20210027426A
(ko)
|
2018-07-03 |
2021-03-10 |
브리스톨-마이어스 스큅 컴퍼니 |
Fgf21 제제
|
|
EP3833766A1
(en)
|
2018-08-09 |
2021-06-16 |
Bioverativ Therapeutics Inc. |
Nucleic acid molecules and uses thereof for non-viral gene therapy
|
|
JP7644007B2
(ja)
|
2018-12-06 |
2025-03-11 |
バイオベラティブ セラピューティクス インコーポレイテッド |
第ｉｘ因子を発現するレンチウイルスベクターの使用
|
|
CN113710229B
(zh)
|
2019-02-25 |
2026-01-06 |
芝加哥大学 |
用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物
|
|
EP3969035A4
(en)
|
2019-05-14 |
2023-06-21 |
Werewolf Therapeutics, Inc. |
SEPARATION UNITS AND METHODS AND THEIR USE
|
|
KR20220097891A
(ko)
|
2019-09-30 |
2022-07-08 |
바이오버라티브 테라퓨틱스 인크. |
렌티바이러스 벡터 제형
|
|
MX2022005666A
(es)
|
2019-11-14 |
2022-10-07 |
Werewolf Therapeutics Inc |
Polipeptidos de citocina activables y metodos de uso de los mismos.
|
|
US20250288542A1
(en)
*
|
2020-10-01 |
2025-09-18 |
The Regents Of The University Of California |
Methods and compositions to treat and prevent viral infections and acute respiratory distress syndrome
|
|
WO2024080306A1
(ja)
*
|
2022-10-11 |
2024-04-18 |
Ｊｃｒファーマ株式会社 |
血清アルブミンと生理活性を有する蛋白質との融合蛋白質
|